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A Nordic WelfAre Model?
The Nordic countries are all established 
welfare states, and there has for some time 
existed a notion of a distinctive Nordic or 
Scandinavian welfare state; it is often under-
stood in terms of broad, tax-financed public 
responsibility and legislated, collective, and 
universalistic solutions that respect employ-
ment interest yet aim at welfare and equity 
goals (1). Lately, the Nordic countries have 
performed well in comparative research 
of health policy in European countries 
(2) but also regarding health care system 
in OECD countries (3). However, while 
it appears that the case for the existence 
of a Nordic model is strong there is actu-
ally no consensus of the precise specifica-
tion of the feature that defines the model 
(1). For example, considerable differences 
seem to exist between the psychiatric ser-
vices within, as well as between, the Nordic 
countries when it comes to history, mental 
health acts and allocation of resources (4). 
Furthermore, some scholars argue that it 
is not even possible to speak of a common 
Nordic political approach to public health, 
since the public health programs in the 
different Nordic countries contain contra-
dictory policies and ideological statements 
(5). This is especially evident for depression 
and sales of antidepressants in the different 
Nordic countries.
depressioN iN the Nordic 
couNtries
Depression is now regarded by the World 
Health Organization to be one of the most 
burdensome diseases in the world and 
deemed a public health priority (6). Overall, 
depression is estimated to have a point prev-
alence of about 5% in a general population, 
and a lifetime risk of about 15% (7). The 
prevalence of depression in the Nordic coun-
tries is believed to vary between 3.5 and 5% 
(8–12). However, information on depression 
prevalence in the different Nordic  countries 
is quite difficult to find and the Nordic 
Governmental Websites does not seem to 
be up-to-date. For example, according to 
the Danish Centre for Health Technology 
Assessment (DACEHTA), the prevalence of 
depression in Denmark is not especially well 
investigated (13) and often relies on earlier 
research suggesting a point prevalence of 
3% of the Danish population or 150 000 
individuals (13, 14). More recent research 
has suggested that the prevalence of major 
depression disorder (MDD) in Denmark 
2000–2006 increased from 2.0 to 4.9% and 
is now suggested to be of public health 
importance (10). The public health concerns 
is also raised in Finland and according to 
the Finnish Health 2000 project over 5% of 
the Finnish population seem to suffer from 
depression (9). Iceland is for some reason 
often not included in Nordic or European 
comparative studies and information on the 
prevalence of depression in Iceland seems 
to be scarce (15). According to information 
on their Website 15–25% of all Icelanders 
can expect to be depressed sometimes in 
their life and 12 000–15 000 individuals 
are predicted to suffer from depression 
at any given moment (10). This is equal 
to 3.8–4.8% of the Icelandic  population. 
In Sweden,  information  provided by the 
Medical Products Agency suggests that 
approximately 5% of the Swedish popu-
lation is afflicted by depression (12). In 
Norway, according to the classic Norwegian 
psychiatric epidemiological HUNT studies, 
depression affects approximately 3.5% of the 
Norwegian population (11).
use of ANtidepressANts
The most common form of treatment of 
depression is antidepressant medication. 
They are currently ranked ninth among pre-
scription drugs with global sales well over 
$20 billion (16). Overall, antidepressant 
prescriptions have risen, but this has been 
offset by a number of patent expiries and 
generic alternatives (17). As Figure 1 shows, 
sales of antidepressants in the Nordic coun-
tries have increased up to fourfold since the 
middle of the 90s (18, 19).
The overall sales of antidepressant 
drugs in the Nordic countries in 2009 (74.1 
DDD/1000 inhabitants per day) is consider-
able higher than the OECD average (52.5), 
but also higher than for example in the UK 
(60.9) (20). However, there are great varia-
tions between the countries, where Iceland 
by far has the highest level of antidepressant 
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Figure 1 | Sales of antidepressants (N06A) in the Nordic Countries during 1995–2011 in DDD*/1000 
inhabitants per day. *Defined Daily Doses according to WHO classification.
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medical approach may seems  questionable, 
but without further research on depression 
prevalence and why antidepressants are 
prescribed it is difficult to assess potential 
public health effects. This is of particu-
lar concern, since antidepressants in the 
absence of therapeutics alternatives are 
projected to continue to dominate the anti-
depressant market to 2018 (17).
Further research is therefore needed to 
scrutinize as to why differences in preva-
lence of depression and antidepressant sales 
exist between the Nordic countries, despite 
the Nordic model. The Nordic countries do 
for some reason have a high consumption 
of antidepressants compared to OECD 
despite relatively moderate or low depres-
sion prevalence patterns. This is especially 
important, since the increase in antidepres-
sants consumption has spurred an ongoing 
debate whether antidepressants are overpre-
scribed (30) (medicalization) or underpre-
scribed (31) (poor access to treatment). 
With the increasing burden of disease due 
to mental disorders worldwide, knowledge 
of the epidemiology of these disorders are 
of increasing interest, and as indicated by 
others scholars (32) the Nordic countries 
have a strong history in this field of research. 
Otherwise valuable Nordic public health 
research may never be performed, despite 
its merits and its potential.
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